{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:24:52Z","timestamp":1792081492282,"version":"4.4.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"NIH\/NIAMS","award":["R01 AR064850"],"award-info":[{"award-number":["R01 AR064850"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Over one-third of patients with RA exhibit evidence of fibromyalgianess, which is associated with higher rates of disability and inadequate responsiveness to RA treatment. Patients with RA often remain on glucocorticoids long-term, despite the known risk of dose-dependent morbidity. We undertook this study to examine the relationship between fibromyalgianess and glucocorticoid persistence among RA patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We followed participants with active RA on oral prednisone for \u223c3\u2009months after initiating a new DMARD. Fibromyalgianess was measured using the Fibromyalgia Survey Questionnaire (FSQ), previously shown to correlate with key FM features often superimposed upon RA. Severity of fibromyalgianess was stratified as follows: FSQ &amp;lt;8 low, FSQ 8\u201310 moderate and FSQ &amp;gt;10 high\/very high. The association between baseline fibromyalgianess and glucocorticoid persistence, defined as prednisone use at 3-month follow-up visit after DMARD initiation, was assessed using multiple logistic regression adjusted for baseline demographics, RA duration, serostatus and inflammatory activity assessed using swollen joint count and CRP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 97 participants on prednisone at baseline, 65% were still taking prednisone at follow-up. Fifty-seven percent of participants with low baseline fibromyalgianess had persistent glucocorticoid use, compared with 84% of participants with high or very high fibromyalgianess. After adjustment for non-inflammatory factors and inflammatory activity, participants with high\/very high baseline fibromyalgianess were more likely to be taking prednisone at follow-up relative to those with low fibromyalgianess [odds ratio 4.99 (95% CI 1.20, 20.73)].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>High fibromyalgianess is associated with persistent glucocorticoid use, independent of inflammatory activity.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keab583","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T11:30:08Z","timestamp":1626867008000},"page":"1556-1562","source":"Crossref","is-referenced-by-count":17,"title":["Fibromyalgianess and glucocorticoid persistence among patients with rheumatoid arthritis"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1802-1427","authenticated-orcid":false,"given":"Beth I","family":"Wallace","sequence":"first","affiliation":[{"name":"Internal Medicine\/Rheumatology, University of Michigan Medical School"},{"name":"VA Ann Arbor Healthcare System, Center for Clinical Management Research , Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriah N","family":"Moore","sequence":"additional","affiliation":[{"name":"Internal Medicine\/Rheumatology, University of Michigan Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C","family":"Heisler","sequence":"additional","affiliation":[{"name":"Internal Medicine\/Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutfiyya N","family":"Muhammad","sequence":"additional","affiliation":[{"name":"Preventive Medicine\/Biostatistics, Northwestern University Feinberg School of Medicine , Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Song","sequence":"additional","affiliation":[{"name":"Internal Medicine\/Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Clauw","sequence":"additional","affiliation":[{"name":"Anesthesiology, University of Michigan Medical School , Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Clifton O","family":"Bingham","sequence":"additional","affiliation":[{"name":"Internal Medicine\/Rheumatology, Johns Hopkins School of Medicine , Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcy B","family":"Bolster","sequence":"additional","affiliation":[{"name":"Internal Medicine\/Rheumatology, Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Marder","sequence":"additional","affiliation":[{"name":"Internal Medicine\/Rheumatology, University of Michigan Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuhina","family":"Neogi","sequence":"additional","affiliation":[{"name":"Internal Medicine\/Rheumatology, Boston University School of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Wohlfahrt","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy D","family":"Dunlop","sequence":"additional","affiliation":[{"name":"Internal Medicine\/Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne C","family":"Lee","sequence":"additional","affiliation":[{"name":"Internal Medicine\/Rheumatology"},{"name":"Preventive Medicine\/Biostatistics, Northwestern University Feinberg School of Medicine , Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"2022062215474513300_keab583-B1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1521-6942(03)00035-4","article-title":"Chronic widespread pain and fibromyalgia: what we know, and what we need to know","volume":"17","author":"Clauw","year":"2003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2022062215474513300_keab583-B2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00296-019-04403-8","article-title":"Performance of 2016 revised fibromyalgia diagnostic criteria in patients with rheumatoid arthritis","volume":"39","author":"Shresher","year":"2019","journal-title":"Rheumatol Int"},{"key":"2022062215474513300_keab583-B3","first-page":"695","article-title":"Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize ra patients with fibromyalgia","volume":"31","author":"Wolfe","year":"2004","journal-title":"J Rheumatol"},{"key":"2022062215474513300_keab583-B4","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/rheumatology\/key075.533","article-title":"Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis","volume":"57","author":"Duffield","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2022062215474513300_keab583-B5","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/acr.23994","article-title":"Association of pain centralization and patient-reported pain in active rheumatoid arthritis","volume":"72","author":"Heisler","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2022062215474513300_keab583-B6","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/art.41440","article-title":"Association of dysregulated central pain processing and response to disease-modifying anti-rheumatic drug therapy in rheumatoid arthritis","volume":"72","author":"Heisler","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2022062215474513300_keab583-B7","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.24430","article-title":"Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis","volume":"61","author":"Ranzolin","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2022062215474513300_keab583-B8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"del Rinc\u00f3n","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2022062215474513300_keab583-B9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/annrheumdis-2011-200702","article-title":"Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis","volume":"71","author":"Dixon","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022062215474513300_keab583-B10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk: relationship to daily and cumulative doses","volume":"39","author":"van Staa","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"2022062215474513300_keab583-B11","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3899\/jrheum.121515","article-title":"Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort","volume":"40","author":"Combe","year":"2013","journal-title":"J Rheumatol"},{"key":"2022062215474513300_keab583-B12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.semarthrit.2019.09.002","article-title":"Patterns of glucocorticoid use and provider-level variation in a commercially insured incident rheumatoid arthritis population","volume":"50","author":"Wallace","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2022062215474513300_keab583-B13","first-page":"1639","article-title":"Variability in glucocorticoid prescribing for rheumatoid arthritis and the influence of provider preference on long-term use","volume":"24","author":"Schmoldt","year":"1975","journal-title":"Arthritis Care Res"},{"key":"2022062215474513300_keab583-B14","doi-asserted-by":"crossref","first-page":"870","DOI":"10.7326\/M20-1594","article-title":"Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis","volume":"173","author":"George","year":"2020","journal-title":"Ann Intern Med"},{"key":"2022062215474513300_keab583-B15","article-title":"Patient characteristics associated with long term glucocorticoid use in a commercially insured incident RA cohort [abstract]","volume":"71","author":"Wallace","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022062215474513300_keab583-B16","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2022062215474513300_keab583-B17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/acr.23266","article-title":"Association between pain sensitization and disease activity in patients with rheumatoid arthritis: a cross-sectional study","volume":"70","author":"Lee","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022062215474513300_keab583-B18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"2022062215474513300_keab583-B19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","article-title":"2016 Revisions to the 2010\/2011 fibromyalgia diagnostic criteria","volume":"46","author":"Wolfe","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2022062215474513300_keab583-B20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3899\/jrheum.180178","article-title":"Biologic and glucocorticoid use after methotrexate initiation in patients with rheumatoid arthritis","volume":"46","author":"George","year":"2019","journal-title":"J Rheumatol"},{"key":"2022062215474513300_keab583-B21","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.39635","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Calabrese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022062215474513300_keab583-B22","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00296-017-3792-4","article-title":"The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis","volume":"37","author":"Salaffi","year":"2017","journal-title":"Rheumatol Int"},{"key":"2022062215474513300_keab583-B23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/rheumatology\/kep458","article-title":"Fibromyalgic rheumatoid arthritis and disease assessment","volume":"49","author":"Pollard","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2022062215474513300_keab583-B24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-015-0525-5","article-title":"A cross-sectional study of pain sensitivity, disease-activity assessment, mental health, and fibromyalgia status in rheumatoid arthritis","volume":"17","author":"Joharatnam","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2022062215474513300_keab583-B25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.rbr.2016.11.004","article-title":"Rheumatoid arthritis seems to have DMARD treatment decision influenced by fibromyalgia","volume":"57","author":"Chakr","year":"2017","journal-title":"Rev Bras Reumatol (Engl Ed)"},{"key":"2022062215474513300_keab583-B26","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/ard.61.7.660","article-title":"Fibromyalgia in patients with rheumatoid arthritis is associated with higher scores of disability","volume":"61","author":"Naranjo","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2022062215474513300_keab583-B27","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/acr.23216","article-title":"Fibromyalgia and the prediction of two-year changes in functional status in rheumatoid arthritis patients","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022062215474513300_keab583-B28","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/art.38682","article-title":"Subgrouping of patients with rheumatoid arthritis based on pain, fatigue, inflammation, and psychosocial factors","volume":"66","author":"Lee","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2022062215474513300_keab583-B29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/acr.23815","article-title":"Tender joint count and inflammatory activity in patients with established rheumatoid arthritis: results from a longitudinal study","volume":"72","author":"Hammer","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022062215474513300_keab583-B30"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab583\/40408142\/keab583.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/4\/1556\/44167389\/keab583.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/4\/1556\/44167389\/keab583.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T09:02:57Z","timestamp":1699261377000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/4\/1556\/6325524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,7,22]]},"published-print":{"date-parts":[[2022,4,11]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab583","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,7,22]]}}}